The Blood-Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults

被引:22
|
作者
Haddad, Nicholas [1 ]
Carr, Maddie [2 ]
Balian, Steve [3 ]
Lannin, James [2 ]
Kim, Yuri [3 ]
Toth, Courtney [4 ]
Jarvis, Jennifer [4 ]
机构
[1] Cent Michigan Univ CMU, Coll Med, Mt Pleasant, MI 48859 USA
[2] Covenant HealthCare, Saginaw, MI 48602 USA
[3] CMU Med Educ Partners, Saginaw, MI 48602 USA
[4] Ascens St Marys Hosp, Saginaw, MI 48601 USA
来源
ANTIBIOTICS-BASEL | 2022年 / 11卷 / 12期
关键词
pharmacokinetics; pharmacodynamics; central nervous system infections; meningitis; ventriculitis; brain abscess; blood-brain barrier; antibiotic; antimicrobial; the specific classes and names of antimicrobial agents discussed in the review; ENTEROCOCCUS-FAECIUM MENINGITIS; BETA-LACTAM ANTIBIOTICS; CEREBROSPINAL-FLUID CONCENTRATIONS; VANCOMYCIN-RESISTANT ENTEROCOCCI; CLINICAL-PRACTICE GUIDELINES; CRITICALLY-ILL PATIENTS; CEREBRAL SPINAL-FLUID; BACTERIAL-MENINGITIS; INTRAVENOUS METRONIDAZOLE; PNEUMOCOCCAL MENINGITIS;
D O I
10.3390/antibiotics11121843
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Bacterial central nervous system (CNS) infections are serious and carry significant morbidity and mortality. They encompass many syndromes, the most common being meningitis, which may occur spontaneously or as a consequence of neurosurgical procedures. Many classes of antimicrobials are in clinical use for therapy of CNS infections, some with established roles and indications, others with experimental reporting based on case studies or small series. This review delves into the specifics of the commonly utilized antibacterial agents, updating their therapeutic use in CNS infections from the pharmacokinetic and pharmacodynamic perspectives, with a focus on the optimization of dosing and route of administration that have been described to achieve good clinical outcomes. We also provide a concise synopsis regarding the most focused, clinically relevant information as pertains to each class and subclass of antimicrobial therapeutics. CNS infection morbidity and mortality remain high, and aggressive management is critical in ensuring favorable patient outcomes while averting toxicity and upholding patient safety.
引用
收藏
页数:37
相关论文
共 50 条
  • [31] Exposure of quantum dots in the nervous system: Central nervous system risks and the blood-brain barrier interface
    Guan, Shujing
    Tang, Meng
    JOURNAL OF APPLIED TOXICOLOGY, 2024, 44 (07) : 936 - 952
  • [32] Crossing the Blood-Brain Barrier: A Review on Drug Delivery Strategies for Treatment of the Central Nervous System Diseases
    Mansor, Nur Izzati
    Nordin, Norshariza
    Mohamed, Farahidah
    Ling, King Hwa
    Rosli, Rozita
    Hassan, Zurina
    CURRENT DRUG DELIVERY, 2019, 16 (08) : 698 - 711
  • [33] Central Nervous System Medications: Pharmacokinetic and Pharmacodynamic Considerations for Older Adults
    Gronich, Naomi
    DRUGS & AGING, 2024, 41 (06) : 507 - 519
  • [34] Next generation of non-mammalian blood-brain barrier models to study parasitic infections of the central nervous system
    Siddiqui, Ruqaiyyah
    Edwards-Smallbone, James
    Flynn, Robin
    Khan, Naveed Ahmed
    VIRULENCE, 2012, 3 (02) : 159 - 163
  • [35] Blood-Brain Barrier Function and Biomarkers of Central Nervous System Injury in Rickettsial versus Other Neurological Infections in Laos
    Dittrich, Sabine
    Sunyakumthorn, Piyanate
    Rattanavong, Sayaphet
    Phetsouvanh, Rattanaphone
    Panyanivong, Phonepasith
    Sengduangphachanh, Amphonsavanh
    Phouminh, Phonelavanh
    Anantatat, Tippawan
    Chanthongthip, Anisone
    Lee, Sue J.
    Dubot-Peres, Audrey
    Day, Nicholas P. J.
    Paris, Daniel H.
    Newton, Paul N.
    Turner, Gareth D. H.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2015, 93 (02): : 232 - 237
  • [36] Involvement of noncoding RNA in blood-brain barrier integrity in central nervous system disease
    Liu, Xi
    Shen, Ling
    Han, Bing
    Yao, Honghong
    NON-CODING RNA RESEARCH, 2021, 6 (03): : 130 - 138
  • [37] Central nervous system complications of diabetes mellitus - A perspective from the blood-brain barrier
    Mooradian, AD
    BRAIN RESEARCH REVIEWS, 1997, 23 (03) : 210 - 218
  • [38] Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery
    Alavijeh M.S.
    Chishty M.
    Qaiser M.Z.
    Palmer A.M.
    NeuroRX, 2005, 2 (4): : 554 - 571
  • [39] Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma
    Galor, Anat
    Ference, Sandra J.
    Singh, Arun D.
    Lee, Michael S.
    Stevens, Glen H. J.
    Perez, Victor L.
    Peereboom, David M.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2007, 144 (01) : 45 - 49
  • [40] Examining the Uptake of Central Nervous System Drugs and Candidates across the Blood-Brain Barrier
    Summerfield, Scott G.
    Zhang, Yanyan
    Liu, Houfu
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2016, 358 (02): : 294 - 305